Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
City of Hope Medical Center
Pfizer
Arcus Biosciences, Inc.
Pfizer
City of Hope Medical Center
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Chinese PLA General Hospital
Abramson Cancer Center at Penn Medicine
University of Southern California
M.D. Anderson Cancer Center
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Abramson Cancer Center at Penn Medicine
University of California, San Francisco
Pancreatic Cancer Action Network
Dana-Farber Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Takara Bio Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Emory University
Lisata Therapeutics, Inc.
University of Chicago
Servier
1200 Pharma, LLC
OHSU Knight Cancer Institute
Sumitomo Pharma America, Inc.
Chinese PLA General Hospital
Mayo Clinic
University of Chicago
Seagen Inc.
Hoffmann-La Roche
M.D. Anderson Cancer Center
University of Colorado, Denver
M.D. Anderson Cancer Center
Rutgers, The State University of New Jersey
Roswell Park Cancer Institute
Panbela Therapeutics, Inc.
National Health Research Institutes, Taiwan
CSPC Ouyi Pharmaceutical Co., Ltd.
Memorial Sloan Kettering Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Washington University School of Medicine
H. Lee Moffitt Cancer Center and Research Institute
Benaroya Research Institute
Theriva Biologics SL